Influence of age upon Ifosfamide-induced nephrotoxicity.
BACKGROUND
Ifosfamide-induced nephrotoxicity is well recognized in children, although it has also been reported in adults. Whether ifosfamide nephrotoxicity is more common in children than in adults is not known.


METHODS
Medical records of adults and children diagnosed with sarcoma whom received ifosfamide with a cumulative dose >20 g/m(2) were evaluated. Twenty-five children (</=18-years of age) and 28 adults were identified.


RESULTS
National Cancer Institute Common Toxicity Criteria grade 3-4 ifosfamide-induced nephrotoxicity was present in 24 and 17% of children and adults, respectively (P = 0.58). Cumulative ifosfamide doses were similar between the two populations, with the median (range) of 70.2 g/m(2) (22.4-72) for children and 59 g/m(2) (20.8-146) for adults (P = 0.25). Logistic regression analysis indicated that neither age or cumulative ifosfamide dose were associated with grade 3-4 ifosfamide-induced nephrotoxicity (P = 0.36).


CONCLUSIONS
Children and adults receiving >20 g/m(2) of ifosfamide have similar susceptibility to ifosfamide-induced nephrotoxicity. Factors other than age and cumulative dose should be considered for understanding the inter-individual variation in nephrotoxicity.
McCune
Jeannine S
JS
University of Washington Medical Center, Seattle, Washington, USA. jmccune@u.washington.edu
Friedman
Debra L
DL
Schuetze
Scott
S
Blough
David
D
Magbulos
Madonna
M
Hawkins
Douglas S
DS
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use / Q000633:toxicity*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use / Q000633:toxicity*; D007223:Infant; D008297:Male; D008875:Middle Aged; D009401:Nephrosis / Q000139:chemically induced*; D012044:Regression Analysis; D012189:Retrospective Studies; D012307:Risk Factors; D012509:Sarcoma / Q000150:complications / Q000188:drug therapy
D018906:Antineoplastic Agents, Alkylating; D007069:Ifosfamide